FibroGen, Inc. - חוב לטווח קצר של החברה FGEN

This short-term liabilities chart demonstrates the resilience of an asset shielded from macroeconomic shocks. The current figure is recorded at 0.00. Business stability relies on the monopoly of the drug Evrenzo in treating anemia. Management efficiency is supported by outsourcing logistics and trials to external contractors, allowing FibroGen, Inc. (FGEN) to focus on deep fibrosis research.

Stable capacity utilization at FibroGen, Inc. (FGEN) enables effective management of credit obligations under one year, reflecting the total volume of loans maturing in less than twelve months. This indicator measures the issuer's current solvency by assessing the company's ability to service short-term debt without compromising operational activities, confirming high liquidity and the quality of the business assets.